BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) is anticipated to release its Q3 2026 results after the market closes on Monday, October 26th. Analysts expect the company to announce earnings of ($0.0886) per share and revenue of $1.02 billion for the quarter. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, October 26, 2026 at 4:30 PM ET.
BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The company had revenue of $989.71 million during the quarter, compared to analyst estimates of $932.03 million. During the same period in the prior year, the company posted $1.44 earnings per share. BioMarin Pharmaceutical’s quarterly revenue was up 20.0% on a year-over-year basis. On average, analysts expect BioMarin Pharmaceutical to post $3.46 EPS for the current fiscal year and $5.16 EPS for the next fiscal year.
BioMarin Pharmaceutical Trading Down 1.2%
Shares of BioMarin Pharmaceutical stock opened at $55.95 on Friday. The stock has a fifty day moving average price of $61.70 and a 200-day moving average price of $58.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 2.39 and a quick ratio of 1.32. BioMarin Pharmaceutical has a 1 year low of $49.26 and a 1 year high of $70.98. The firm has a market cap of $10.83 billion, a PE ratio of 33.71, a P/E/G ratio of 0.46 and a beta of 0.22.
Analyst Ratings Changes
A number of equities research analysts recently issued reports on the company. HC Wainwright restated a “neutral” rating and issued a $60.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Citigroup increased their target price on BioMarin Pharmaceutical from $75.00 to $76.00 and gave the company a “buy” rating in a research note on Thursday, July 16th. Canaccord Genuity Group lifted their price target on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock a “buy” rating in a research note on Monday, August 10th. Oppenheimer boosted their target price on BioMarin Pharmaceutical from $95.00 to $97.00 and gave the company an “outperform” rating in a research note on Friday, August 7th. Finally, Weiss Ratings lowered shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, September 18th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $88.60.
Get Our Latest Stock Analysis on BMRN
About BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company’s research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.
BioMarin’s marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.
Read More
- Five stocks we like better than BioMarin Pharmaceutical
- Spotify Soars After Earnings as the Company Touts AI Benefits and Moderating Costs
- Lockheed Martin’s Record $292 Billion Backlog Comes With a Delivery Test
- Palantir’s Next Big Test Isn’t a Partnership—It’s the Numbers
- Kinder Morgan’s $4.7 Billion Pipeline Bet Could Be Bigger Than Its Earnings Beat
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
